Biotech

All Articles

Ideaya bags option on Biocytogen bispecific ADC in $400M bargain

.Ideaya Biosciences is betting $400 million in biobucks that a bispecific antibody-drug conjugate (A...

Takeda takes $140M loss on fallen short epilepsy medication, promotes FDA operate

.Our company actually understand that Takeda is actually expecting to locate a path to the FDA for e...

VBI Vaccinations declare insolvency, looks for resource sale

.Immunology biotech VBI Vaccines is drifting dangerously near the point of no return, with strategie...

Celldex anti-cKIT antibody minimize colonies in one more period 2 research study

.It is actually not easy to muscle mass in on a room as affordable as immunology, yet Celldex Therap...

Boehringer provides to $1.3 B for checkpoint prevention biotech

.Boehringer Ingelheim is actually providing to $1.3 billion for Nerio Therapeutics and also a precli...

Ventyx's last resort for inflamed med sides in Crohn's failure

.Ventyx Biosciences' Crohn's condition medicine performed certainly not aid patients attain remissio...

Cognition's stage 2 beam data tarnish Alzheimer's prospect

.Knowledge Therapies' phase 2 SHINE trial has taken a few of the luster off the Alzheimer's conditio...

BMS centers bispecific months after filing to run period 3 trial

.Bristol Myers Squibb has actually possessed a whiplash change of mind on its own BCMA bispecific T-...

Charles Baum manages Terremoto as chief executive officer

.Charles Baum, M.D., Ph.D., who managed Mirati Therapeutics' $ 5.8 billion sale to Bristol Myers Squ...

Asarina to shut after efforts to companion Tourette's medication fail

.After reaching out to greater than 200 providers to companion a Tourette disorder therapy that show...